Addition of ruxolitinib and decitabine to modified busulfan/cyclophosphamide conditioning regimen for prophylaxis relapse in high-risk acute myeloid leukemia: the phase 2 prospective study
Annals of Hematology · 2024
DOI: 10.1007/s00277-024-05972-w ↗At a glance
Klinische Studie (Phase II) in Annals of Hematology, 2024. Written by Yujun Wei and 11 co-authors. Institution: School of Medicine, Nankai University, Tianjin, 300071, China. Major MEDLINE topics: Decitabine, Leukemia, Myeloid, Acute, Transplantation Conditioning, Busulfan. Cited 3 times so far (Crossref); 42 references. Funded by: National Natural Science Foundation of China, Beijing Natural Science Foundation of China, Beijing Nova Program.
Abstract (original language)
Niciun rezumat disponibil.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- School of Medicine, Nankai University, Tianjin, 300071, China.
- Chief Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100071, China.
- Department of Hematology, The First Medical Center of Chinese PLA General Hospital, Beijing, 100853, China.
- Chief Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100071, China. lipingruirui@163.com.
- School of Medicine, Nankai University, Tianjin, 300071, China. daihongrm@163.com.
- Chief Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100071, China. daihongrm@163.com.
Funding
- National Natural Science Foundation of China
- Beijing Natural Science Foundation of China
- Beijing Nova Program
- National Key Research and Development Program of China
- Military medical support innovation and generate special program
- Special Research Found for Health Protection
Cite
APA
Wei, Y., Qian, K., Le, N., Wang, L., Li, F., Luan, S., Wang, L., Jin, X., Peng, B., Wang, N., Dou, L., & Liu, D. (2024). Addition of ruxolitinib and decitabine to modified busulfan/cyclophosphamide conditioning regimen for prophylaxis relapse in high-risk acute myeloid leukemia: the phase 2 prospective study. Annals of Hematology. https://doi.org/10.1007/s00277-024-05972-w
Vancouver
Wei Y, Qian K, Le N, Wang L, Li F, Luan S, et al. Addition of ruxolitinib and decitabine to modified busulfan/cyclophosphamide conditioning regimen for prophylaxis relapse in high-risk acute myeloid leukemia: the phase 2 prospective study. Annals of Hematology. 2024. doi:10.1007/s00277-024-05972-w
BibTeX
@article{Wei2024,
author = {Wei, Yujun and Qian, Kun and Le, Ning and Wang, Lili and Li, Fei and Luan, Songhua and Wang, Lu and Jin, Xiangshu and Peng, Bo and Wang, Nan and Dou, Liping and Liu, Daihong},
title = {Addition of ruxolitinib and decitabine to modified busulfan/cyclophosphamide conditioning regimen for prophylaxis relapse in high-risk acute myeloid leukemia: the phase 2 prospective study},
journal = {Annals of Hematology},
year = {2024},
doi = {10.1007/s00277-024-05972-w}
}
EUVIMED